Prenatal hypoxia-induced adaptation and neuroprotection that is inducible nitric oxide synthase-dependent.
The incidence of perinatal stroke is approximately 0.025%. About two thirds of these patients develop long-lasting neurological deficits. Preconditioning-induced neuroprotection, a phenomenon in which application of a stimulus induces brain ischemic tolerance, is investigated to improve outcome after a perinatal stroke. We applied prenatal hypoxia to fetuses by exposing 22-day pregnant mother rats to 15% oxygen for 30 min and subjected newborns with or without this prenatal hypoxia to brain ischemia 48 h later. Newborns with the prenatal hypoxia had a lower mortality rate, less brain tissue and neuronal loss and fewer active caspase 3 (an indicator for cell apoptosis) positive brain cells than newborns with the brain ischemia only. This neuroprotection was abolished by an inhibitor of inducible nitric oxide synthase (iNOS). The expression of iNOS proteins but not endothelial and neuronal NOS proteins was increased by the prenatal hypoxia. Thus, the prenatal hypoxia-induced neuroprotection may be iNOS-dependent.
Zhao
Ping
P
Department of Anesthesiology, Neuroscience and Neurological Surgery, University of Virginia, One Hospital Drive, PO Box 800710, Charlottesville, VA 22908-0710, USA.
Zuo
Zhiyi
Z
D000222:Adaptation, Physiological / Q000502:physiology*; D000818:Animals; D000831:Animals, Newborn; D017209:Apoptosis / Q000502:physiology; D001238:Asphyxia Neonatorum / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D020520:Brain Infarction / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control; D053148:Caspase 3; D020169:Caspases / Q000378:metabolism; D004195:Disease Models, Animal; D005260:Female; D005311:Fetal Hypoxia / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D006801:Humans; D020925:Hypoxia-Ischemia, Brain / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D007231:Infant, Newborn; D019194:Ischemic Preconditioning / Q000379:methods*; D009410:Nerve Degeneration / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control; D009569:Nitric Oxide / Q000096:biosynthesis; D052247:Nitric Oxide Synthase Type II / Q000037:antagonists & inhibitors / Q000378:metabolism*; D011247:Pregnancy; D051381:Rats; D017207:Rats, Sprague-Dawley; D016896:Treatment Outcome
D009569:Nitric Oxide; D052247:Nitric Oxide Synthase Type II; C505407:CASP3 protein, human; C505410:Casp3 protein, rat; D053148:Caspase 3; D020169:Caspases